Ibutilide: Difference between revisions
Bmurray990 (talk | contribs) |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established'' | |||
==Special Populations== | ==Special Populations== | ||
| Line 28: | Line 29: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2-12h | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: Mostly urine | ||
*Mechanism of Action: Class III - Prolongs AP and refractory period | *Mechanism of Action: Class III - Prolongs AP and refractory period | ||
| Line 44: | Line 45: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Cardiology]] | ||
Latest revision as of 20:30, 22 September 2019
General
- Type: Antiarrhythmics
- Dosage Forms:IV 1mg/10mL
- Common Trade Names: Corvert
Adult Dosing
- Loading dose = 1mg IV in 50mL D5W over 10min (wt>60kg)
- Loading dose = 0.01mg/kg IV in 50mL D5W over 10min (wt<60kg)
- Dose may be repeated 10min after completion of 1st dose
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: Use in pregnancy may be considered, but data is sparse
- Lactation risk: Not recoemmended
- Renal Dosing: none
- Hepatic Dosing: none
Indications
- Rapid conversion of recent-onset A-fib/flutter to NSR
Contraindications
- Allergy to class/drug
Adverse Reactions
- QT prolongation, V-tach, torsades
- Observe for 4hr after infusion
Pharmacology
- Half-life: 2-12h
- Metabolism: Hepatic
- Excretion: Mostly urine
- Mechanism of Action: Class III - Prolongs AP and refractory period
Kinetics
- Onset of action = 20-30min
- Duration of action = 24hr